Edgewise Therapeutics (EWTX) Assets Average (2021 - 2026)
Edgewise Therapeutics (EWTX) posted Assets Average of $535.6 million for Q1 2026, down 5.72% sequentially from $568.0 million in Q4 2025, and up 13.8% YoY from $470.6 million in Q1 2025.
Edgewise Therapeutics (EWTX) Assets Average (2021 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Assets Average for 6 years, with the latest figure at $535.6 million in Q1 2026.
- Quarterly Assets Average rose 13.8% year-over-year to $535.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $535.6 million (up 13.8% YoY) and the FY2025 annual result came in at $519.7 million, up 25.71% from the prior year.
- Assets Average slipped to $535.6 million in Q1 2026 per EWTX's latest filing, from $568.0 million in the prior quarter.
- Over five years, Assets Average peaked at $598.4 million in Q3 2025 and troughed at $265.1 million in Q2 2022.
- A 5-year average of $428.9 million and a median of $446.9 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2024: Assets Average slipped 13.76% in 2022, then soared 62.45% in 2024.
- Over 5 years, Assets Average stood at $372.1 million in 2022, then declined by 12.48% to $325.7 million in 2023, then jumped by 53.22% to $499.0 million in 2024, then gained by 13.82% to $568.0 million in 2025, then decreased by 5.72% to $535.6 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $535.6 million, $568.0 million, and $598.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 499.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 499.11 Mn |
| Mar 31, 2026 | 535.56 Mn |
| Dec 31, 2025 | 568.03 Mn |
| Sep 30, 2025 | 598.40 Mn |
| Jun 30, 2025 | 533.86 Mn |
| Mar 31, 2025 | 470.60 Mn |
| Dec 31, 2024 | 499.05 Mn |
| Sep 30, 2024 | 521.46 Mn |
| Jun 30, 2024 | 542.73 Mn |
| Mar 31, 2024 | 446.92 Mn |
| Dec 31, 2023 | 325.70 Mn |
| Sep 30, 2023 | 320.99 Mn |
| Jun 30, 2023 | 338.51 Mn |
| Mar 31, 2023 | 356.75 Mn |
| Dec 31, 2022 | 372.13 Mn |
| Sep 30, 2022 | 317.28 Mn |
| Jun 30, 2022 | 265.07 Mn |
| Mar 31, 2022 | 278.99 Mn |
| Dec 31, 2021 | 289.84 Mn |
| Sep 30, 2021 | 298.97 Mn |